Study: FDG-PET reigns supreme for assessing Alzheimer’s

FDG-PET is superior to amyloid PET imaging with the radiopharmaceutical florbetapir for assessing cognitive decline in patients with Alzheimer's disease or mild cognitive impairment. By Erik L. Ridley, AuntMinnie staff writer

Read More


PET scans indicate women may have higher Alzheimer’s risk than men

“The differences that we observed indicate the strong possibility that there are sex differences in the structural and functional connections in the brain, which may contribute to women’s increased risk for Alzheimer’s,” said Sepideh Shokouhi, at the Alzheimer’s Association International Conference in Los Angeles. Matt O'Connor | Molecular Imaging | www.healthimaging.com

Read More


JAMA: Amyloid PET changed clinical management in 60% of patients with dementia

GCG Global Healthcare suggested reading: Amyloid PET imaging greatly influenced the clinical management of patients with mild cognitive impairment (MCI) and dementia, according to the first phase of a multicenter trial published April 2 in JAMA. The findings may have important implications for diagnosing and managing Alzheimer’s disease. By Matt O'Connor | Molecular Imaging

Read More

About Us

GCG Global Healthcare are specialists in healthcare excellence. Driven by a desire to improve healthcare and clinical solutions for everyone – patients, medical professionals and facilities. Gloreen G at GCG has vast experience and understanding of the specialist medical and diagnostic imaging market. This gives GCG the ability to ensure that you receive the very best salary and incentives package, including leave entitlements, days off, paid conferences and radiology expenses.